LeadStory

CNBC

Pfizer experimental sickle cell drug fails phase 3 trial

CNBC · Just In
CNBC
CNBC
Just In

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on drugmaker Pfizer.

Breakdown
  • Pfizer's experimental sickle cell drug failed a phase 3 trial. 9s
  • The drug was part of Pfizer's $5.5 billion acquisition of Global Blood Therapeutics. 22s
  • Pfizer previously withdrew Oxbryta, the only approved medicine from the acquisition, due to safety concerns. 31s
  • One more sickle cell drug from the acquisition remains in phase 3 development. 1m 4s
  • Sickle cell disease has limited treatment options, and there is hope for more accessible therapies. 1m 13s
HealthMedical Research